Synthetic viability of homologous recombination-deficient cancers

Project Information

SYNVIA

Grant agreement ID: 681572

DOI

10.3030/681572

Project closed

EC signature date 13 April 2016

Start date 1 July 2016

End date 30 June 2021

Funded under

• EXCELLENT SCIENCE - European Research Council (ERC)

Total cost

€ 1 999 437,50

EU contribution

€ 1 999 437,50

Coordinated by

UNIVERSITAET BERN
Switzerland

CORDIS provides links to public deliverables and publications of HORIZON projects.

Links to deliverables and publications from FP7 projects, as well as links to some specific result types such as dataset and software, are dynamically retrieved from OpenAIRE .

Publications

Peer reviewed articles (16)

PARP Inhibitor Efficacy Depends on CD8 + T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer

Author(s): Constantia Pantelidou, Olmo Sonzogni, Mateus De Oliveria Taveira, Anita K. Mehta, Aditi Kothari, Dan Wang, Tanvi Visal, Michelle K. Li, Jocelin Pinto, Jessica A. Castrillon, Emily M. Cheney, Peter Bouwman, Jos Jonkers, Sven Rottenberg, Jennifer L. Guerriero, Gerburg M. Wulf, Geoffrey I. Shapiro
Published in: Cancer Discovery, Issue 9/6, 2019, Page(s) 722-737, ISSN 2159-8274
Publisher: American Association for Cancer Research Inc.
DOI: 10.1158/2159-8290.cd-18-1218

Functional Radiogenetic Profiling Implicates ERCC6L2 in Non-homologous End Joining

Author(s): Paola Francica, Merve Mutlu, Vincent A. Blomen, Catarina Oliveira, Zuzanna Nowicka, Anika Trenner, Nora M. Gerhards, Peter Bouwman, Elmer Stickel, Maarten L. Hekkelman, Lea Lingg, Ismar Klebic, Marieke van de Ven, Renske de Korte-Grimmerink, Denise Howald, Jos Jonkers, Alessandro A. Sartori, Wojciech Fendler, J. Ross Chapman, Thijn Brummelkamp, Sven Rottenberg
Published in: Cell Reports, Issue 32/8, 2020, Page(s) 108068, ISSN 2211-1247
Publisher: Cell Press
DOI: 10.1016/j.celrep.2020.108068

Progression through mitosis promotes PARP inhibitor-induced cytotoxicity in homologous recombination-deficient cancer cells

Author(s): Pepijn M. Schoonen, Francien Talens, Colin Stok, Ewa Gogola, Anne Margriet Heijink, Peter Bouwman, Floris Foijer, Madalena Tarsounas, Sohvi Blatter, Jos Jonkers, Sven Rottenberg, Marcel A. T. M. van Vugt
Published in: Nature Communications, Issue 8, 2017, Page(s) 15981, ISSN 2041-1723
Publisher: Nature Publishing Group
DOI: 10.1038/ncomms15981

Genetic Dissection of Cancer Development, Therapy Response, and Resistance in Mouse Models of Breast Cancer

Author(s): Stefano Annunziato, Marco Barazas, Sven Rottenberg, Jos Jonkers
Published in: Cold Spring Harbor Symposia on Quantitative Biology, Issue 81, 2016, Page(s) 141-150, ISSN 0091-7451
Publisher: Cold Spring Harbor Laboratory Press
DOI: 10.1101/sqb.2016.81.030924

Selected Alkylating Agents Can Overcome Drug Tolerance of G 0 -like Tumor Cells and Eradicate BRCA1-Deficient Mammary Tumors in Mice

Author(s): Marina Pajic, Sohvi Blatter, Charlotte Guyader, Maaike Gonggrijp, Ariena Kersbergen, Aslι Küçükosmanoğlu, Wendy Sol, Rinske Drost, Jos Jonkers, Piet Borst, Sven Rottenberg
Published in: Clinical Cancer Research, Issue 23/22, 2017, Page(s) 7020-7033, ISSN 1078-0432
Publisher: American Association for Cancer Research
DOI: 10.1158/1078-0432.CCR-17-1279

EZH2 promotes degradation of stalled replication forks by recruiting MUS81 through histone H3 trimethylation

Author(s): Beatrice Rondinelli, Ewa Gogola, Hatice Yücel, Alexandra A. Duarte, Marieke van de Ven, Roxanne van der Sluijs, Panagiotis A. Konstantinopoulos, Jos Jonkers, Raphaël Ceccaldi, Sven Rottenberg, Alan D. D’Andrea
Published in: Nature Cell Biology, Issue 19/11, 2017, Page(s) 1371-1378, ISSN 1465-7392
Publisher: Nature Publishing Group
DOI: 10.1038/ncb3626

BRCA-deficient mouse mammary tumor organoids to study cancer-drug resistance

Author(s): Alexandra A Duarte, Ewa Gogola, Norman Sachs, Marco Barazas, Stefano Annunziato, Julian R de Ruiter, Arno Velds, Sohvi Blatter, Julia M Houthuijzen, Marieke van de Ven, Hans Clevers, Piet Borst, Jos Jonkers, Sven Rottenberg
Published in: Nature Methods, Issue 15/2, 2017, Page(s) 134-140, ISSN 1548-7091
Publisher: Nature Publishing Group
DOI: 10.1038/nmeth.4535

Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality

Author(s): Ewa Gogola, Alexandra A. Duarte, Julian R. de Ruiter, Wouter W. Wiegant, Jonas A. Schmid, Roebi de Bruijn, Dominic I. James, Sergi Guerrero Llobet, Daniel J. Vis, Stefano Annunziato, Bram van den Broek, Marco Barazas, Ariena Kersbergen, Marieke van de Ven, Madalena Tarsounas, Donald J. Ogilvie, Marcel van Vugt, Lodewyk F.A. Wessels, Jirina Bartkova, Irina Gromova, Miguel Andújar-Sánchez, Jiri Ba
Published in: Cancer Cell, Issue 33/6, 2018, Page(s) 1078-1093.e12, ISSN 1535-6108
Publisher: Cell Press
DOI: 10.1016/j.ccell.2018.05.008

Haploid genetic screens identify genetic vulnerabilities to microtubule-targeting agents

Author(s): Nora M. Gerhards, Vincent A. Blomen, Merve Mutlu, Joppe Nieuwenhuis, Denise Howald, Charlotte Guyader, Jos Jonkers, Thijn R. Brummelkamp, Sven Rottenberg
Published in: Molecular Oncology, Issue 12/6, 2018, Page(s) 953-971, ISSN 1574-7891
Publisher: Elsevier BV
DOI: 10.1002/1878-0261.12307

The CST Complex Mediates End Protection at Double-Strand Breaks and Promotes PARP Inhibitor Sensitivity in BRCA1-Deficient Cells

Author(s): Marco Barazas, Stefano Annunziato, Stephen J. Pettitt, Inge de Krijger, Hind Ghezraoui, Stefan J. Roobol, Catrin Lutz, Jessica Frankum, Fei Fei Song, Rachel Brough, Bastiaan Evers, Ewa Gogola, Jinhyuk Bhin, Marieke van de Ven, Dik C. van Gent, Jacqueline J.L. Jacobs, Ross Chapman, Christopher J. Lord, Jos Jonkers, Sven Rottenberg
Published in: Cell Reports, Issue 23/7, 2018, Page(s) 2107-2118, ISSN 2211-1247
Publisher: Cell Press
DOI: 10.1016/j.celrep.2018.04.046

New tools for old drugs: Functional genetic screens to optimize current chemotherapy

Author(s): Nora M. Gerhards, Sven Rottenberg
Published in: Drug Resistance Updates, Issue 36, 2018, Page(s) 30-46, ISSN 1368-7646
Publisher: Churchill Livingstone
DOI: 10.1016/j.drup.2018.01.001

The shieldin complex mediates 53BP1-dependent DNA repair

Author(s): Sylvie M. Noordermeer, Salomé Adam, Dheva Setiaputra, Marco Barazas, Stephen J. Pettitt, Alexanda K. Ling, Michele Olivieri, Alejandro Álvarez-Quilón, Nathalie Moatti, Michal Zimmermann, Stefano Annunziato, Dragomir B. Krastev, Feifei Song, Inger Brandsma, Jessica Frankum, Rachel Brough, Alana Sherker, Sébastien Landry, Rachel K. Szilard, Meagan M. Munro, Andrea McEwan, Théo Goullet de Rugy,
Published in: Nature, Issue 560/7716, 2018, Page(s) 117-121, ISSN 0028-0836
Publisher: Nature Publishing Group
DOI: 10.1038/s41586-018-0340-7

Mechanisms of PARP inhibitor resistance in cancer and insights into the DNA damage response

Author(s): Paola Francica, Sven Rottenberg
Published in: Genome Medicine, Issue 10/1, 2018, ISSN 1756-994X
Publisher: BioMed Central
DOI: 10.1186/s13073-018-0612-8

The ASCIZ-DYNLL1 axis promotes 53BP1-dependent non-homologous end joining and PARP inhibitor sensitivity

Author(s): Jordan R. Becker, Raquel Cuella-Martin, Marco Barazas, Rui Liu, Catarina Oliveira, Antony W. Oliver, Kirstin Bilham, Abbey B. Holt, Andrew N. Blackford, Jörg Heierhorst, Jos Jonkers, Sven Rottenberg, J. Ross Chapman
Published in: Nature Communications, Issue 9/1, 2018, ISSN 2041-1723
Publisher: Nature Publishing Group
DOI: 10.1038/s41467-018-07855-x

Radiosensitivity is an acquired vulnerability of PARPi-resistant BRCA1-deficient tumors

Author(s): Marco Barazas, Alessia Gasparini, Yike Huang, Asli Küçükosmanoğlu, Stefano Annunziato, Peter Bouwman, Wendy Sol, Ariena Kersbergen, Natalie Proost, Renske de Korte-Grimmerink, Marieke van de Ven, Jos Jonkers, Gerben R Borst, Sven Rottenberg
Published in: Cancer Research, 2018, Page(s) canres.2077.2018, ISSN 0008-5472
Publisher: American Association for Cancer Research
DOI: 10.1158/0008-5472.can-18-2077

Replication Fork Remodeling and Therapy Escape in DNA Damage Response-Deficient Cancers

Author(s): Martin Liptay, Joana S. Barbosa, Sven Rottenberg
Published in: Frontiers in Oncology, Issue 10, 2020, ISSN 2234-943X
Publisher: Frontiers Media S. A.
DOI: 10.3389/fonc.2020.00670